The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

The cancer portfolio also put in a buoyant ... climbed 41 per cent to £101 million. The latter product will of course not have an impact on GSK's future growth, as it is one of the oncology ...

GSK plc (NYSE:GSK) develops and markets a wide range of healthcare products, including vaccines, specialty medicines, and general medicines. Its portfolio includes prescription drugs, over-the-counter ...

“Emma led the executive team and the wider organisation to deliver continued, improved operating performance in 2024, with GSK’s reshaped product portfolio demonstrating both strength and ...

Bearish flow noted in GSK (GSK) Pharma with 5,611 puts trading, or 3x expected. Most active are Mar-25 36.5 puts and 3/14 weekly 39.5 calls, with total volume in those strikes near 6,100 contracts.

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other pharmaceutical stocks. Almost no other industry goes as far as the phrase "defensive" as the ...

LONDON, Feb 27 (Reuters) - British drugmaker GSK (GSK.L), opens new tab will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such ...

("GSK" or the "Company") (NYSE ... Provide specific products and services to you, such as portfolio management or data aggregation. Develop and improve features of our offerings.